No need to login to view prices!
|Create new account|
Due to technical maintenance the webshop is closed until January 4th, 2020. We wish you a successful 2021!
IPSWICH, Mass., June 14, 2018 /PRNewswire/ -- New England Biolabs (NEB®) today announced the release of the NEBNext® Single Cell/Low Input RNA Library Prep Kit for Illumina®. This new kit incorporates an optimized template switching protocol— as well as NEB's Ultra™ II FS enzymatic DNA fragmentation technology— to produce full-length transcript sequence-ready libraries from single cells and ultra-low input RNA.
"Studies based on population analyses using thousands of cells disguise the potentially significant biological variations among sub-populations of cells and in individual cells, and the benefits of sequencing the transcriptomes of these smaller samples is clear," said Fiona Stewart, NEBNext Portfolio Manager at NEB. "However, there is a need for more sensitive, reliable and affordable products for library preparation for single cell and ultra-low input RNA samples, in order to increase the breadth of transcripts detected, and the reliability of that transcript detection, as well as enabling distinction between sample variation and experimental variation."
"To address this growing need, we've incorporated a unique protocol and suite of reagents in our NEBNext Single Cell/Low Input RNA Library Prep Kit to reliably handle cultured or primary cells, with the flexibility also to accommodate as little as 2 pg, but up to 200 ng, of total RNA," said Stewart. "The inclusion of NEB's Ultra II FS technology further streamlines the workflow and minimizes sample loss to enable robust full-length transcript sequence-ready library generation. We see significantly more transcripts, and especially see an improvement in detection of low-abundance transcripts. The substantially higher yields achieved also allow the use of fewer PCR cycles."
The NEBNext Single Cell/Low Input RNA Library Prep Kit meets the needs of operations at any scale, and with a range of sample types, according to reports by early access users.
"We recently have developed and implemented a novel single cell transcriptomics pipeline to support our single cell research initiatives, including the Human Cell Atlas project," explained Peter Ellis, Senior Staff Scientist at the Wellcome Sanger Institute. "Fully deployed, this high-throughput pipeline will be capable of generating single cell RNA-seq data from approximately 30,000 samples per month. The scale of this operation is made possible by combining the streamlined workflows of the NEBNext Single Cell/Low Input Kit with our expertise in high-throughput liquid handling and sample processing."
Dr. Sarah Teichmann, the head of cellular genetics at the Wellcome Sanger Institute added, "The implementation of this new single cell RNA-seq pipeline is an important addition to our core Scientific Operations and will enable our scientists to resolve at scale the transcriptional variation within a wide variety of single cells."
The NEBNext Single Cell/Low Input RNA Library Prep Kit's workflow includes new reagents, combined steps and minimized cleanup steps, making it fast and easy to use, with less than 30 minutes hands-on time. Downstream of cDNA synthesis, sequencing library construction incorporates the Ultra II FS technology, allowing users to perform enzymatic cDNA fragmentation, end repair, and dA-tailing reactions in a single enzyme mix, with a single protocol. A module with reagents only for cDNA synthesis and amplification is also available.
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.